YD Bio Limited has announced that its subsidiary, YD Bio USA, Inc., has entered into a master strategic alliance agreement with YC Biotech Co Ltd to establish a cross-border regulatory platform focused on US Food and Drug Administration (FDA) submissions.
Under the agreement, YD Bio USA will act as the exclusive US Agent and official liaison to the US Food and Drug Administration for YC Biotech’s Contract Research Organization (CRO) clients across Asia. The collaboration is designed to create a streamlined regulatory pathway for companies seeking US market access.
The partnership will support a broad range of FDA-related filings, including Investigational New Drug (IND), New Drug Application (NDA), and Biologics License Application (BLA) submissions. It will also cover medical device pathways such as Investigational Device Exemption (IDE), 510(k), De Novo and Premarket Approval (PMA) filings. In addition, the alliance will provide strategic advisory services, including pre-IND meeting facilitation, FDA inspection readiness and ongoing regulatory strategy support.
As part of its responsibilities, YD Bio USA will manage official communications with the FDA, represent sponsors in regulatory meetings, advise on US regulatory pathways and compliance risks, and coordinate inspection preparedness activities. YC Biotech will lead project acquisition and technical execution in Asia, including preparation of submission dossiers, compilation of Chemistry, Manufacturing and Controls (CMC) documentation, development of clinical protocols, scientific writing and overall project management to maintain regulatory timelines.
The companies describe the collaboration as establishing a “Taiwan–US dual-core” regulatory platform that integrates YC Biotech’s execution capabilities in Asia with YD Bio USA’s experience engaging US regulators. The alliance aims to offer a one-stop solution for cross-border regulatory submissions.
The agreement also marks a structural evolution in YD Bio’s business model, shifting from a single-project advisory approach to a scalable platform strategy. The company indicated that the framework could expand to include additional Asian CRO partners, potential engagement with the European Medicines Agency (EMA), and the development of a broader US clinical network.
Company leadership stated that the alliance is intended to enhance innovation and strengthen support for biopharma partners navigating complex regulatory requirements. YD Bio noted early momentum in its regulatory pipeline, with multiple projects progressing through INTERACT, pre-IND and IND meetings.
YD Bio Limited is a US-anchored public biotechnology company building an integrated healthcare platform spanning regulated diagnostics, clinical services and commercial healthcare markets. The company operates DNA methylation-based oncology testing programmes in the United States under an LDT-first strategy and provides compliant life sciences distribution and clinical trial supply chain services to pharmaceutical and biotechnology partners.
